AU2008342920B2 - Topical application and formulation of erythropoietin for skin wound healing - Google Patents

Topical application and formulation of erythropoietin for skin wound healing Download PDF

Info

Publication number
AU2008342920B2
AU2008342920B2 AU2008342920A AU2008342920A AU2008342920B2 AU 2008342920 B2 AU2008342920 B2 AU 2008342920B2 AU 2008342920 A AU2008342920 A AU 2008342920A AU 2008342920 A AU2008342920 A AU 2008342920A AU 2008342920 B2 AU2008342920 B2 AU 2008342920B2
Authority
AU
Australia
Prior art keywords
epo
gel
formulation
wound
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008342920A
Other languages
English (en)
Other versions
AU2008342920A1 (en
Inventor
Augustinus Bader
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2008342920A1 publication Critical patent/AU2008342920A1/en
Assigned to AUGUSTINUS BADER reassignment AUGUSTINUS BADER Request for Assignment Assignors: HERAEUS KULZER GMBH
Application granted granted Critical
Publication of AU2008342920B2 publication Critical patent/AU2008342920B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/434—Inhibitors, antagonists of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008342920A 2007-12-28 2008-12-20 Topical application and formulation of erythropoietin for skin wound healing Active AU2008342920B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07025167.3 2007-12-28
EP07025167 2007-12-28
PCT/EP2008/010978 WO2009083203A2 (de) 2007-12-28 2008-12-20 Topische anwendung und formulierung von erythropoietin für die wundheilung der haut

Publications (2)

Publication Number Publication Date
AU2008342920A1 AU2008342920A1 (en) 2009-07-09
AU2008342920B2 true AU2008342920B2 (en) 2014-09-18

Family

ID=40751089

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008342920A Active AU2008342920B2 (en) 2007-12-28 2008-12-20 Topical application and formulation of erythropoietin for skin wound healing

Country Status (11)

Country Link
US (1) US9101586B2 (https=)
EP (1) EP2222327B1 (https=)
JP (1) JP5553769B2 (https=)
CN (1) CN101951944B (https=)
AU (1) AU2008342920B2 (https=)
BR (1) BRPI0821814A2 (https=)
CA (1) CA2709545C (https=)
DK (1) DK2222327T3 (https=)
ES (1) ES2625145T3 (https=)
RU (1) RU2465003C2 (https=)
WO (1) WO2009083203A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5869219B2 (ja) 2007-08-16 2016-02-24 レメドー バイオメッド リミテッド 治療および美容適用のためのエリスロポイエチンおよびフィブロネクチン組成物
EP2590666B1 (en) 2010-07-06 2017-04-26 Augustinus Bader Topical application of erythropoietin for use in the treatment of injuries of the cornea
WO2012031778A1 (de) 2010-09-12 2012-03-15 Augustinus Bader Verwendung von erythropoietin bei der heilung von wunden oder gewebedefekten ohne narbenbildung
EP2919805B1 (en) * 2012-11-14 2022-01-05 Smith & Nephew, Inc. Stable thermolysin hydrogel
AU2014235578B2 (en) 2013-03-15 2017-08-17 Smith & Nephew, Inc. Dissolvable gel-forming film for delivery of active agents
CA2909956C (en) * 2013-04-30 2021-06-01 University Of Southern California Accelerated healing of eye injuries by angiotensin peptides
WO2015075406A1 (en) * 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers
AU2016314611C1 (en) * 2015-09-04 2019-12-19 Remedor Biomed Ltd. Topical erythropoietin formulations and methods for improving wound healing with and cosmetic use of the formulations
RU2611401C1 (ru) * 2015-10-28 2017-02-21 Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России) Способ получения лекарственного средства с эритропоэтином местного действия
WO2017104725A1 (ja) * 2015-12-16 2017-06-22 第一三共株式会社 創傷治療剤
ES2952448T3 (es) 2016-11-10 2023-10-31 Asc Regenity Ltd Formulaciones cosméticas para aplicaciones tópicas que contienen moléculas derivadas de eritropoyetina
RU2679446C2 (ru) * 2017-03-16 2019-02-11 Алексей Валерьевич Люндуп Способ лечения синдрома диабетической стопы
GB201720320D0 (en) 2017-12-06 2018-01-17 Univ Of Sussex Tissue repair
RU2754383C1 (ru) * 2020-12-07 2021-09-01 Федеральное Государственное Бюджетное Учреждение "Национальный Медицинский Исследовательский Центр Эндокринологии" Министерства Здравоохранения Российской Федерации (Фгбу "Нмиц Эндокринологии" Минздрава России) Способ лечения неинфицированного послеоперационного раневого дефекта стопы при отсутствии признаков критической ишемии конечности у больных с нейропатической и нейроишемической формой синдрома диабетической стопы
CN112961821B (zh) * 2021-02-24 2023-05-30 四川大学华西医院 三维培养血管内皮细胞的方法
CN115177782B (zh) * 2021-04-02 2023-07-18 诺一迈尔(山东)医学科技有限公司 一种高透气、促愈合的液体创可贴及其制备方法
EP4395797A4 (en) 2022-06-29 2025-09-03 Biostem Tech Inc MICRONIZED WOUND HEALING COMPOSITIONS PREPARED FROM INTACT HUMAN AMNION-CHORION TISSUES HAVING AN INTACT INTERMEDIATE SPONGE LAYER POSITIONED BETWEEN THEM

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025221A1 (en) * 1992-06-11 1993-12-23 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
WO2005063965A1 (de) * 2003-12-30 2005-07-14 Bionethos Holding Gmbh Verfahren zur regeneration von gewebe
WO2005070451A1 (en) * 2004-01-22 2005-08-04 Zafena Aktiebolag Pharmaceutical composition comprising non-glycosylated erythropoietin
WO2006089056A2 (en) * 2005-02-16 2006-08-24 Alza Corporation Apparatus and method for transdermal delivery of erythropoetin-based agents
US20080247987A1 (en) * 2005-08-04 2008-10-09 Angiotech International Ag Block Copolymer Compositions and Uses Thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0850051A2 (en) 1995-08-31 1998-07-01 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
JP2000095678A (ja) * 1998-09-22 2000-04-04 Dai Ichi Kogyo Seiyaku Co Ltd パップ剤用基剤およびそれを含有するパップ剤
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
JP5144876B2 (ja) * 2002-06-20 2013-02-13 バーダー、アウグスティヌス 増殖因子を用いて、および生物学的マトリクスあるいは支持構造を用いて細胞を増殖および分化する方法およびデバイス
DE10260873A1 (de) * 2002-12-23 2004-07-15 Beiersdorf Ag Selbstklebende Polymermatrix mit einem Gehalt an Meeresalgenextrakt und Glycerin
EP1548031A1 (en) * 2003-12-22 2005-06-29 Dubai Genetics FZ-LLC Nature-identical erythropoietin
DE10361813A1 (de) * 2003-12-30 2005-09-08 Bionethos Holding Gmbh Verfahren zur Regeneration von Gewebe
CA2582255A1 (en) * 2004-08-30 2006-08-08 Lunamed, Inc. 4-phenylbutyric acid controlled-release formulations for therapeutic use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025221A1 (en) * 1992-06-11 1993-12-23 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
WO2005063965A1 (de) * 2003-12-30 2005-07-14 Bionethos Holding Gmbh Verfahren zur regeneration von gewebe
WO2005070451A1 (en) * 2004-01-22 2005-08-04 Zafena Aktiebolag Pharmaceutical composition comprising non-glycosylated erythropoietin
WO2006089056A2 (en) * 2005-02-16 2006-08-24 Alza Corporation Apparatus and method for transdermal delivery of erythropoetin-based agents
US20080247987A1 (en) * 2005-08-04 2008-10-09 Angiotech International Ag Block Copolymer Compositions and Uses Thereof

Also Published As

Publication number Publication date
DK2222327T3 (en) 2017-05-15
CN101951944B (zh) 2015-04-01
EP2222327B1 (de) 2017-02-15
RU2465003C2 (ru) 2012-10-27
RU2010130890A (ru) 2012-02-10
CA2709545C (en) 2013-10-29
AU2008342920A1 (en) 2009-07-09
US20100278916A1 (en) 2010-11-04
CA2709545A1 (en) 2009-07-09
BRPI0821814A2 (pt) 2015-06-16
EP2222327A2 (de) 2010-09-01
US9101586B2 (en) 2015-08-11
ES2625145T3 (es) 2017-07-18
WO2009083203A2 (de) 2009-07-09
WO2009083203A3 (de) 2010-02-18
CN101951944A (zh) 2011-01-19
JP5553769B2 (ja) 2014-07-16
JP2011507920A (ja) 2011-03-10

Similar Documents

Publication Publication Date Title
AU2008342920B2 (en) Topical application and formulation of erythropoietin for skin wound healing
EP0928206B1 (en) A hydrocolloid wound gel
RU2240830C1 (ru) Раневое покрытие и способ его получения
Bhatnagar et al. Delivery systems for platelet derived growth factors in wound healing: A review of recent developments and global patent landscape
EP2059206B1 (en) Dry wound dressing and drug delivery system
US20230372579A1 (en) Methods for treating wounds
PT1107791E (pt) Composições de hidrogel para a administração com libertação controlada de factores de crescimento
BRPI0717734B1 (pt) Método para preparar um pó seco de nanopartículas poliméricas, pó seco e uso do mesmo
Valachova et al. Skin wound healing with composite biomembranes loaded by tiopronin or captopril
US11938173B2 (en) Use of Clostridium histolyticum protease mixture in promoting wound healing
TWI773927B (zh) 促進及治療慢性傷口癒合之組合物及方法
CZ20032011A3 (cs) Použití nemetabolizovatelného cukru a polymerového absorpčního činidla pro podporu buněčné rekonstrukce a/nebo buněčné diferenciace
CN121081602B (zh) SjP40蛋白的应用、促进皮肤组织修复的组合物及其制备方法、药物制剂
RU2778646C1 (ru) Композиция для лечения инфицированных ран различного генеза и способ ее получения
Palácio et al. WOUND HEALING EFFECTS OF Β-LAPACHONE-LOADED LIPOSOMAL HYDROGEL BASED ON BACTERIAL CELLULOSE AND HYDROXYETHYLCELLULOSE
KR20230136597A (ko) 상처 치료를 위한 조성물들 및 방법들
Santhan A Comparative Study between Efficacy Of Topical Sucralfate And 5% Povidone Iodine In Chronic Lower Limb Ulcers
Coto Hyaluronic Acid and Wound Healing

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: AUGUSTINUS BADER

Free format text: FORMER APPLICANT(S): HERAEUS KULZER GMBH

FGA Letters patent sealed or granted (standard patent)